Long-term vs. short-term treatment with vitamin K antagonists for VTE

A JAMA Clinical Evidence Synopsis looked at the length of treatment with vitamin K antagonists (VKAs) for recurrent venous thromboembolism. The meta-analysis involved 11 randomized clinical trials and more than 3,700 patients. Warfarin was the most commonly used VKA; however, acenocoumarol, fluindione, and sodium dicoumarol were also investigated. According to the findings, long-term VKA therapy (at least 3 months) was associated with lower rates of thromboembolic events compared with short-term VKA therapy.